We aimed to study the effect of elapsed time from AML diagnosis to treatment (TDT) on OS in a group of patients from public Hospital in Brazil. 41 AML (23 M,18 F, 41 yrs, 18 - 84 yrs, from 2001 to 2004). There were 38 de novo AML and 3 secondary, median TDT was 6 days (range 1 - 82 d); the young ones were treated earlier than old ones (TDT 4 days vs 11, p=0.07). Longer TDT (>10 d) was associated with worse CR rates (p=0.02) and OS (p=0.04). When patients were categorized into TDT from 1 - 4 d (I) vs >5 (II), those from I presented better OS than II (p=0.004). When TDT was longer than 7 days OS decreased even more. Hb was higher in patients with TDT I vs II (8.3 vs 7.5 g/dL, p=0.03) but WBC (p=0.34) and platelet count (p=0.75) were not different. Patients with TDT of 10 d were younger than TDT >10 d (median age 41 vs 70 yrs, p=0.001). The OS was 15.1% in 2 yrs and 8.6% in 7 yrs. Our data suggest longer TDT, when analyzed continuously, predicted for lower CR rates and OS rates.
Cite this paper
L. Pelloso, S. Rohr, M. Yamamoto and M. Chauffaille, "Time Elapsed from AML Diagnosis to Induction Chemotherapy Affects Overall Survival," Journal of Cancer Therapy, Vol. 4 No. 5, 2013, pp. 957-960. doi: 10.4236/jct.2013.45108.
 D. Grimwade, H. Walker, G. Harrison, et al., “The Predictive Value of Hierarchical Cytogenetic Classification in Older Adults with Acute Myeloid Leukemia (AML): Analysis of 1065 Patients Entered into the United Kingdom Medical Research Council AML 11 Trial,” Blood, Vol. 98, No. 5, 2001, pp. 1312-1320.
 P. D. Kottaridis and R. E. Gale, Frew “The Presence of a FLT3 Internal Tandem Duplication in Patients with Acute Myeloid Leukemia (AML) Adds Important Prognostic Information to Cytogenetic Risk Group and Response to the First Cycle of Chemotherapy: Analysis of 854 Patients from the United Kingdom Medical Research Council AML 10 and 12 Trials,” Blood, Vol. 98, No. 6, 2001, pp. 1752-1759. doi:10.1182/blood.V98.6.1752
 M. A. Sekeres, P. Elson, M. E. Kaylacio, et al., “Time from Diagnosis to Treatment Initiation Predicts Survival in Younger, But Not Older, Acute Myeloid Leukemia Patients,” Blood, Vol. 113, No. 1, 2009, pp. 28-36.
 E. M. Fagundes, V. Rocha and A. B. Glória, et al., “De Novo Acute Myeloid Leukemia in Adults Younger than 60 Years of Age: Socioeconomic Aspects and Treatment Results in a Brazilian University Center,” Leukemia & Lymphoma, Vol. 47, No. 8, 2006, pp. 1557-1564.
 W. Pulcheri, N. Spector, M. Nucci, et al., “The Treatment of Acute Myeloid Leukemia in Brazil: Progress and Obstacles,” Haematologica, Vol. 80, No. 2, 1995, pp. 130-135.
 L. A. Pelloso, M. de L. Chauffaille, F. S. Ghaname, et al., “Karyotype in Acute Myeloid Leukemia: Importance and Type of Aberrations in 30 Patients at Diagnosis,” Revista da Associa??o Médica Brasileira, Vol. 49, No. 2, 2003, pp. 150-155. doi:10.1590/S0104-42302003000200032
 C. A. Rodrigues, M. L. Chauffaille, L. A. Pelloso, et al., “Acute Myeloid Leukemia in Elderly Patients: Experience of a Single Center,” Brazilian Journal of Medical and Biological Research, Vol. 36, No. 6, 2003, pp. 703-708. doi:10.1590/S0100-879X2003000600004
 A. Kanamaru, Y. Takemoto, M. Tanimoto, H. Muramaki, N. Asou, T. Kobayashi, K. Kuriyama, E. Ohmoto, H. Sakamaki, K. Tsubari, A. Hiraoka, O. Yamada, H. Oh, K. Saito, S. Matsuda, K. Minato, T. Ueda, O. Ohno and Japan Study Group, “All Trans Retinoic Acid for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia,” Blood, Vol. 85, No. 5, 1995, pp. 1202-1206.
 F. R. Appelbaum, H. Gundacker, D. R. Head, et al., “Age and Acute Myeloid Leukemia,” Blood, Vol. 107, No. 9, 2006, pp. 3481-3485. doi:10.1182/blood-2005-09-3724
 G. Juliusson, et al., “Most 70-to 79-Year-Old Patients with Acute Myeloid Leukemia Do Benefit from Intensive Treatment,” Blood, Vol. 117, No. 12, 2011, pp. 3473-3474. doi:10.1182/blood-2010-11-321737